Database→Omiganan
Tier 2-3AntimicrobialSkinAnti-inflammatoryPREMIUM

Omiganan

Omiganan Pentahydrochloride (CLS001 / MBI 226) -- Synthetic Cationic Antimicrobial Peptide, Indolicidin Analog
Not FDA-approved for any indication. Not EMA-approved. Most advanced synthetic antimicrobial peptide (AMP) in clinical development by trial count, with completed Phase 3 trials in catheter-site infection prevention and papulopustular rosacea, and completed Phase 2 trials in acne, atopic dermatitis, seborrheic dermatitis, and HPV-induced genital lesions. The Phase 3 catheter trial (NCT00231153) did not demonstrate superiority over povidone-iodine on the primary endpoint (bloodstream infection rates). The rosacea Phase 3 showed statistically significant lesion reduction vs. vehicle. No regulatory submission has resulted in approval. Not on WADA Prohibited List.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Omiganan is a synthetic 12-amino acid cationic peptide derived from indolicidin, an antimicrobial peptide from bovine neutrophil granules. It shares the cathelicidin protein family with the human peptide LL-37 (profiled separately), but its direct structural parent is the bovine indolicidin, not LL-37. Omiganan has the broadest clinical trial record of any synthetic antimicrobial peptide: Phase 3 for catheter infection prevention (missed primary endpoint) and papulopustular rosacea (statistically significant vs. vehicle), Phase 2 for acne vulgaris (positive), atopic dermatitis (microbiome recovery without clinical improvement), seborrheic dermatitis (negative vs. placebo), and HPV-induced anogenital lesions (96.6% HPV viral load reduction in anogenital warts, p=0.045). No indication has achieved regulatory approval.

🔒

Full Profile: Premium Members Only

The complete Omiganan profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use